Agenus | AGEN - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 29.06B 523M 2025-12
Agenus USD 133.44M 514K 2025-12
Amgen USD 29.06B 1.17B 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Celldex Therapeutics USD 534.66M 69.68M 2025-12
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Intrexon USD 23.72M 45.04M 2024-06
J&J USD 55.62B 1.01B 2025-12
Jiangsu Hengrui CNY 51.4B 4.64B 2025-09
Karyopharm Therapeutics USD 89.75M 8.12M 2025-09
MacroGenics USD 219.94M 12.15M 2025-12
Merck EUR 13.23B 354M 2025-12
Merck USD 47.56B 10.49B 2025-09
Northwest Biotherapeutics USD 7.2M 1.04M 2025-09
Novartis USD 30.46B 2.26B 2025-12
Novavax USD 978.28M 3.69M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Veracyte USD 488.38M 39.15M 2025-12